A Pan-Cancer Analysis of GAPDH as a Common Biomarker for Various Cancers  

作　　者：Yasir Hameed 

机构地区：[1]Department of Biotechnology,Institute of Biochemistry,Biotechnology,and Bioinformatics,The Islamia University of Bahawalpur,Pakistan

出　　处：《Proceedings of Anticancer Research》2024年第5期105-120,共16页抗癌研究

摘　　要：Objective:To investigate the expression levels of glyceraldehyde-3-phosphate dehydrogenase(GAPDH)and explore its prognostic value across 24 different human cancers.This investigation was conducted using comprehensive bioinformatics and in vitro approaches,incorporating multiple layers of analysis.Methods:GAPDH expression and methylation levels were assessed using bioinformatics tools and validated in cell lines through RNA-seq and targeted bisulfite-seq analyses.The potential prognostic significance of GAPDH was evaluated using the KM plotter.Additionally,cBioPortal was employed to investigate genetic alterations associated with this gene.Pathway analysis was conducted using DAVID.Furthermore,a correlation analysis between GAPDH expression and CD8+T immune cells was performed using TIMER and CDT.Finally,a gene-drug interaction network analysis was conducted using Cytoscape to examine the relationship between GAPDH and various drugs.Results:GAPDH was found to be commonly upregulated in 24 types of human cancers,with its upregulation significantly correlated with poor relapse-free survival(RFS)and overall survival(OS)in BLCA,CESC,HNSC,KIRP,LIHC,and LUAD.This suggests that GAPDH plays a significant role in the development of these cancers.GAPDH upregulation was also associated with various clinicopathological features in patients with BLCA,CESC,HNSC,KIRP,LIHC,and LUAD.Pathway analysis revealed GAPDH’s involvement in diverse pathways.Additionally,notable correlations were observed between GAPDH expression and its promoter methylation level,genetic alterations,and CD8+T immune cell levels.Moreover,several regulatory drugs targeting GAPDH were identified,with the potential to modulate its expression and potentially prevent conditions such as BLCA,CESC,HNSC,KIRP,LIHC,and LUAD.Conclusion:Based on our findings,GAPDH emerges as a promising diagnostic and prognostic biomarker for BLCA,CESC,HNSC,KIRP,LIHC,and LUAD.

关 键 词：CANCER Expression GAPDH BIOMARKER 

分 类 号：R73[医药卫生—肿瘤]